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SurR9-C84AThe chronic systemic administration of D-Galactose in C57BL/6J mice showed a relatively high oxidative stress,
amyloid-β expression and neuronal cell death. Enhanced expression of pyknotic nuclei, caspase-3 and reduced
expression of neuronal integrity markers further conﬁrmed the aforesaid insults. However, concomitant treat-
ment with the recombinant protein (SurR9-C84A) and the anti-transferrin receptor antibody conjugated
SurR9-C84A (SurR9 + TFN) nanocarriers showed a signiﬁcant improvement in the disease status and neuronal
health. The beauty of this study is that the biodegradable Food and Drug Administration (FDA) approved
poly(lactic-co-glycolic acid) (PLGA) nanocarriers enhanced the biological half-life and the efﬁcacy of the treat-
ments. The nanocarriers were effective in lowering the amyloid-β expression, enhancing the neuronal integrity
markers andmaintaining the basal levels of endogenous survivin that is essential for evading the caspase activa-
tion and apoptosis. The current study herein reports for the ﬁrst time that the brain targeted SurR9-C84A
nanocarriers alleviated the D-Galactose induced neuronal insults and has potential for future brain targeted
nanomedicine application.
© 2015 Published by Elsevier B.V.1. Introduction
A chronic systemic administration of D-Galactose (D-Gal) induces
the natural ageing process in animals characterized by the features of
reduced lifespan [1,2], cognitive impairment [3,4], oxidative stress [5],
compromised immunity [6], formation of advanced glycation end
products (AGEs) [7,8] and neurodegeneration [9]. Added to this, aged
individuals are reported to be much more susceptible to many of the
chronic diseases such as the neurodegenerative type and themitochon-
drial free radical toxicity [10]. A theory is also in existence which states
that ageing and its associated disorders are a result of the free radical
induced damage to the cellular components and that there exists no de-
fence machinery with them to counteract this stress [11]. Eventually,
the damaged mitochondria losses its integrity and becomes inefﬁcient
progressively, secretingmore of the free radicals. Ageing is a substantialterase; AD, Alzheimer's disease;
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war).risk factor for the development of Alzheimer's disease (AD) which
typically falls under the category of neurodegeneration. A probable
clariﬁcation for this is that ageing positively inﬂuences the neuronal
degeneration by enhancing the oxidative stress, protein accumulation,
reducing their enzymatic clearance, and interrupting the calcium
homeostasis affecting the mitochondrial functioning [12]. AGEs are a
cluster of diverse compounds formed from the non-enzymatic catalysis
of the reducing sugars (glucose, fructose etc.) with the amino acids
present in proteins, DNA or lipids [13]. These AGEs were found to accu-
mulate as the ageing progresses and are associated with a number of
age related diseases such as neurodegeneration [14,15]. D-Galactose is
one such compound obtained as a nutrient (e.g. lactose in milk) and
synthesised in the body where it forms glycolipids and glycoproteins.
In general, it is metabolised by D-galactokinase and galactose-1-
phosphate uridyltransferase to non-toxic compounds [5]. But, at levels
above the normal range, it is metabolised to galactitol by aldose reduc-
tase that reacts abnormally with the amino acids forming AGEs [16].
Chronic D-Gal administration also activates the acetyl cholinesterase
(AChE) activitywhich rapidly degrades the acetylcholine in the synaptic
cleft. Subsequently, there is a decrease in the cholinergic stimulation
that leads to an enhanced inﬂammatory response, tissue damage and
cognitive impairment [17,18]. These symptoms characterise the AD
generation with the hallmark representation of amyloid beta (Aβ) pep-
tide extracellular deposition and intracellular neuroﬁbrillary tangles
[19]. Since, the chronic D-Gal administration induced senescence is asso-
ciated with neurodegeneration it would, therefore, be an appropriate
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associated AD. On the other hand, delivery of therapeutic com-
pounds to the brain is always challenging due to the presence of
the blood brain barrier (BBB). Only the compounds possessing
small molecular mass below the 400 Da size and high lipophilicity
can cross it and satisfying these requirements for a conventional
therapeutic is quiet difﬁcult. Hence, the ideal way to deliver the drugs is
to encapsulate them inside the nanoparticles and customise them with
the brain speciﬁc markers. This would eventually enhance the bioavail-
ability and protect them from enzymatic degradation, enabling the deliv-
ery of maximum pay load [20,21]. The poly (lactic-co-glycolic acid)
(PLGA) polymer has been used for the preparation of nanoparticles on ac-
count of its bio-compatibility and feasibility for surface functionalization.
The PLGA nanoparticles have gained enormous reputation for the
formulation of several drugs and also were approved by the US Food
and Drug Administration (FDA) for clinical application [22–25].
In the present study, D-Gal (120 mg/kg) was administered to the
animals to induce neuronal injury mimicking the ageing associated
AD. The activities of themutant protein SurR9-C84A and its targeted for-
mulation have not been tested before in the D-Gal induced AD model.
The mutant SurR9-C84A is a recombinant protein that belongs to the
family of inhibitor of apoptosis proteins (IAPs) family and shows
bi-functional activity (apoptotic or mitotic) depending on the basal
levels of wild type survivin [24]. In summary, the current study aimed
to investigate the neuroprotector activity of SurR9-C84A protein and
compared them against the positive control melatonin. Melatonin
(N-acetyl-5-methoxytryptamine) is a hormone secreted from the
pineal gland and it acts against ageing because of its ability to mitigate
mitochondrial malfunction and oxidative stress [26].
2. Materials and methods (see supplementary Section 1)
2.1. Nanoparticle preparation and characterization
The SurR9-C84A loaded PLGA nanoparticles (NPs) were prepared
and characterized as described earlier [27]. In brief, a 1% w/v of PLGA
polymer in ethyl acetate was prepared and added to the 1% polyvinyl
alcohol (PVA) containing 10 mg/ml of protein to give the initial W/
O emulsion. Then, the ﬁnal volume of 15 ml of PVA was added to
yield the W/O/W emulsion which was stirred at 800 RPM overnight
at 4 °C to yield the NPs. Later, they are centrifuged, collected, freeze
dried and stored for future use. The void NPs used for the in vivo
study were prepared using the same procedure except that they
were devoid of the proteins used. The transferrin receptor antibody
conjugated SurR9-C84A loaded targeted NPs were prepared using
the carbodiimide chemistry. In this technique, the free carboxyl
groups of the PLGA NPs were incubated with the 0.1 M 1-ethyl-3-
[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) and
0.7 M N-hydroxysulfosuccinimide (NHS) mix for 4 h at RT. Following
this, the surface activated NPs were incubated with mouse monoclonal
transferrin receptor antibody (OX26, Santa Cruz) overnight at 4 °C. The
next day, nanoparticles were washed in sterile milliQ water to remove
the unbound antibody, collected, freeze dried and stored at 4 °C for
future use.
2.2. Animals and experimental design
C57BL/6J mice were maintained in colony cages with free access to
food and sterile water, under standardized housing conditions (natural
light–dark cycle, temperature of 23 ± 1 °C, relative humidity of 55 ±
5%). All the animals used in the study were acclimatized to laboratory
conditions prior to the experiments and were randomly assigned to
the following experimental groups (n = 6).
1) Untreated control; 2) D-Gal disease group (120 mg/kg body
weight (BW); 3) D-Gal + melatonin (1 mg/kg BW); 4) D-Gal + Void
NPs (1.5 mg/kg BW); 5) D-Gal + SurR9-C84A NPs (1.5 mg/kg BW);and 6) D-Gal+ TFN SurR9-C84ANPs (1.5mg/kg BW). D-Galwas admin-
istered daily by intraperitoneal injection for 6weeks and the treatments
were given through intravenous route in the last twoweeks. The dose of
melatonin (1 mg/kg BW) was reported in the study of Shen et al. [28]
while the rest were ﬁxed based on a tolerated dose conducted. The
entire in vivo study was performed strictly following the guidelines as
recommended for the care and use of laboratory animals of the National
Institutes of Health (NIH). The experimental protocol was approved by
the Institutional animal ethical committee (IAEC), Kakatiya University,
Warangal.
2.3. Behavioural tests
2.3.1. Locomotor activity
Amajority of the CNS therapeutics inﬂuence the locomotor activ-
ity in both the animals and man and hence is a good indicative of the
brain functioning. This activity is studied using an actophotometer
embeddedwith the photoelectric cells that are connected in a circuit.
The recordings were noted soon after the animal moves and cut offs
the light beam falling on the photocell. On the test date, animals
were placed individually in the activity cage and monitored before
and after 30 min of drug administration for assessing the locomotor
activity [29].
2.3.2. Rotarod test
The rotarod apparatus is awidely accepted experimentalmethod for
evaluating the locomotor coordination in mice as neurodegeneration is
associated with a signiﬁcant decline in motor control. In this study,
a ﬁve-station accelerating rota-rod (model ENV-575M, St. Albans) has
been adopted for testing the grip strength.
Initially, the animals were trained prior on the rota rod at a speed of
24 rpm for 2 min following which another trial is repeated. The mice
were sufﬁciently trained before proceeding for actual recording post
drug treatments. Each testing session consisted of at least 5 trials per
mouse per day with a gap of 30 min between the trials. The recordings
were made soon after the mice began to fall from the apparatus
interrupting the infrared beam.
2.4. Gene analysis (see supplementary Section 1.3)
2.4.1. Immunohistochemistry for various markers (see supplementary
Section 1.4)
2.4.1.1. Statistical analysis. One-way and two-way ANOVA with Tukey's
post-hoc test was employed for calculating the statistical difference
and the results with ‘p’ less than 0.05 were considered as statistically
signiﬁcant.
3. Results
3.1. Nanoparticle preparation and characterization
The prepared NPs were characterized for the shape andmorphology
using the scanning electron microscopy. As observed from Fig. 1A, all
the prepared NPs were spherical in shape with an average size of
150 nm that are ideal for the brain penetration [24]. The NPs were
then tested to see the integrity of the protein encapsulated, along
with the successful binding of transferrin receptor antibody. The
successful encapsulation of SurR9-C84A inside the NPs was clearly
visible as observed from Fig. 1B. To differentiate this, the protein
only (SurR9-C84A) and void nanoparticle gel images are also shown.
Further, the NP surface modiﬁcation was found to be around 74%
(Fig. 1C) and this is also detectable with the presence of transferrin an-
tibody heavy and light chains (Fig. 1B). The targeted NPswere also eval-
uated for internalization in the SK-N-SH neurons and were observed to
be successfully uptaken within 30 min post-incubation (Fig. 1D).
Fig. 1. Characterization of targeted nanoparticles. A) Scanning electron microscopic images of the prepared PLGA NPs. All of the images showed smooth spherical morphology with an
average size of 150 nm. B) SDS-Gel image conﬁrming the successful encapsulation of SurR9-C84A inside the nanoparticles. The targeted NPs were also observed to have the heavy and
light chain bands of anti-transferrin receptor antibody conﬁrming the successful surface modiﬁcation. SurR9-C84A protein only and void nanoparticle bands are also shown.
C) Confocal microscopic image of the anti-transferrin antibody conjugated SurR9-C84A loaded NPs. Rabbit anti-mouse FITC (green channel) showing the presence of antibody on the
surface of theNPs. D) The targetedNPswere incubatedwith the differentiated SK-N-SH neurons andwere found to be internalizedwithin 30min. Arrow heads indicating the internalized
nanoparticles.
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Demonstrating its neuroprotective activity, SurR9-C84A was able
rescue the neurons from the D-Gal induced toxicity. As observed from
Fig. 2, D-Gal induced a signiﬁcant 13.8 fold increment in the β-amyloid
protein expression while pre-treatment with the SurR9-C84A prior to
D-Gal insult lowered the expression by 4.5 folds (p b 0.05). The same
was compared against the positive control, melatonin which showed a
reduced expression of β-amyloid by 3.7 folds. In addition to this, D-Gal
insults also showed a reduced expression of β-tubulin III (Fig. 2C),
a neuronal integrity marker by 2.7 folds compared to the untreated
control, while SurR9-C84A and melatonin increased its expression by
1.4 and 1.5 folds respectively post D-Gal insults (Fig. 2D).3.3. Behavioural analysis and gene expression
The D-Gal induced effect on motor coordination was studied
using the rotarod and the mice showed random grip strengths for
the ﬁrst four weeks where no treatments were started. However,
during the treatment period (5th week), improvement in the grip
strengths were observed for melatonin and SurR9 + TFN groups
that showed a 1.24 and 1.28 folds improvement compared to the dis-
eased control (Fig. 3A). The locomotory activity showed a drastic
change in the 6th week, where D-Gal showed the least activity as
counted by the photobeam interruptions. A noticeable improvement
was however observed for melatonin, SurR9-C84A and SurR9 + TFN
groups (Fig. 3B) with 1.3, 1.17, and 1.26 fold increased crossings. As
observed from Fig. 3C, D-Gal induced the enhanced expression APP,APOE and GSK-3 by 16, 67 and 25 folds respectively indicating the
degenerative onset. Also, the apoptotic marker caspase-3 showed a
maxim of 46% increase in the disease control. However, SurR9-
C84A treatment showed maximum expression of wild type survivin
and its splice variant (Sur3β) along with the neuronal integrity
markers NF 68 and NF 200. The targeted SurR9-C84A treatment
was very effective in lowering the pathologic APP, GSK-3 and apoptotic
caspase-3 markers (Fig. 3C).3.4. Immunohistochemistry for various markers
As observed, the control group showed no abnormal neuronal cell
morphology but the D-Gal insult group showed enlarged intercellular
spaces, pyknotic nucleus, light cytoplasmic staining and capillaries
surrounded by erythrocytes (Fig. 4A). However, an evident improve-
ment in the neural cell morphology was observed in the treatment
groups more speciﬁcally with the SurR9 + TFN group (Fig. 4A). The
void only control, showed similar patterns as observed with D-Gal
insult, conﬁrming the effective protein therapy (Fig. 4A). Further sub-
stantiating the results, D-Gal only treated control showed intense im-
munoreactivity for pathologic β-amyloid, Cas-3 (Fig. 4A), excitatory
amino acid transporter, glutamate and NMDA receptors (Fig. 4B) and
endogenous survivin (Fig. 4C) while the neuronal integrity markers
NF 68 and NF 200 showed a lighter reactivity (Fig. 4C). However, treat-
ment groups signiﬁcantly improved the neuronal recovery as observed
from the stainings of survivin, NF 68 and NF 200 (Fig. 4C). Compared to
the non-targeted treatment group, the targeted SurR9 + TFN was
effective and showed a slightly improved outcome (Fig. 4A–D).
Fig. 2. Protective actions of SurR9-C84A against D-Galactose induced insults in vitro. A) Microscopic images of SK-N-SH neurons post D-Galactose insults; scale bar = 10 μm.
B) Flowcytometry analysis forβ-amyloid expression post D-Gal insults. C) Flowcytometry analysis for β-tubulin III expression post D-Gal insults. D) Histogram showing theﬂowcytometry
for β-amyloid and β-tubulin III expression. Overall, D-Gal induced signiﬁcant increase in the expression of β-amyloid and lowered the β-tubulin III expression that was respectively
nulliﬁed by SurR9-C84A actions, *p b 0.05 is considered statistically signiﬁcant.
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As observed from Fig. 4E, a major proportion (~800 ng/ml) of the
targeted anti-transferrin SurR9-C84A was accumulated in the brain.
This is 25% more compared to the accumulation in any of the tissues
considered and is because of the abundant availability of the TFN recep-
tors in the brain [30]. Hence, it is believed that the surface functionalized
SurR9-C84A have shown better permeation, bioavailability and efﬁcacy
compared to the non-conjugated SurR9-C84A treatment. Surprisingly,
the non-conjugated SurR9-C84A showed very less brain permeation
and is explained because of its enhanced accumulation in the bone,
blood, liver and spleen (Fig. 4E).
3.6. Immunoﬂuorescence for glial ﬁbrillary acidic protein (GFAP)
To further substantiate the protective actions of the various proteins
studied, immunoﬂuorescence staining was performed for the GFAP
protein. Surprisingly, GFAP was observed to be highly expressed in the
D-Gal disease control that constituted to 4.8 folds increase compared
to the untreated mice (Fig. 5A) p b 0.001.
Intriguing results weremarkedwith the treated groups that showed
a strong decrement in the GFAP levels denoting reduced occupancy
of reactive astrocytes (Fig. 5A). Detailed expression is shown in
Supplementary Figure S1A & B.
4. Discussion
Themutant SurR9-C84Aprotein belonging to the class of inhibitor of
apoptotic proteins (IAPs) has shown to be potentially neuroprotective
targeting the wild type survivin in the neurons. The mechanisticpathwaybehind its protectionwas reported as, neurons being postmitotic
cells, possess negligible endogenous survivin pool and upon treatment,
SurR9-C84A behaves indistinguishable to the wild type and shows
its protective activity [27,31–33]. Hence, the nanoencapsulation of
SurR9-C84A along with a batch of surface modiﬁed, anti-transferrin
receptor antibody conjugated, SurR9-C84A NPs were formulated
and their efﬁcacy was evaluated for addressing the D-Gal insult. The
prime reason for using the NPs is to provide stability to the protein ther-
apeutics, while the conjugation with anti-transferrin receptor antibody
guided theNPs for brain speciﬁc delivery. Transferrin is one of the abun-
dantly available brain speciﬁc targets expressed on the brain capillary
endothelium and hence is an attractive ligand for nanoparticle conjuga-
tion [30]. Considering the potential in vitro activity of SurR9-C84A, we
tried to investigate its possible neuroprotective actions against D-Gal in-
duced insults for which an extensive literature exists [34–37]. The basic
mechanism behind the cause of neurodegeneration is explained as,
chronic exposure of D-Gal leads to overproduction of ROS following its
oxidative metabolism generating AGEs [38]. AGEs are considered as
the resultant by-products of the addition reactions that occur between
the reduced sugars (D-Gal in this case) and free amine groups present
on the polypeptides and lipids. The dreadful events appear soon after
the formation of AGEs and their binding to the receptors for AGEs
(RAGE) in the cells and tissues.
Thus, it results in the protein aggregation that is highly implicated in
AD [39]. On the other hand, to improve the drug availability inside the
brain, surface modiﬁed, anti-transferrin receptor antibody conjugated
SurR9-C84A NPs were used. Transferrin receptor is reported to be one
of the speciﬁc receptor expressed on the brain endothelium and
has attracted a lot of attention for fabricating brain targeted deliveries
[40,41]. The characterization of NPs revealed that all of them have a
size below 150 nm which is ideal for brain penetration (Fig. 1A) and
Fig. 3. The behavioural improvement following the treatmentwith various nanoformulations. A) Themotor coordination following the insultswith D-Gal and treatmentswere analysed for
6weeks. For theﬁrst 4weeks randomised grip strengthswere observed but however, treatmentswithmelatonin and SurR9+TFN showed an improvement in the time spent by themice.
B) The locomotory activity also diminished following D-Gal insults but a noticeable recovery was observed for melatonin, SurR9-C84A and SurR9 + TFN groups. C) Gene expression
analysis uncovered increased expression of genes involved in neuronal insult and protection. As observed from this ﬁgure (panel C), D-Gal induced the enhanced expression of pathologic
(APP, APOE and GSK-3) and apoptotic genes (caspase-3) following D-Gal only insult. However, there was a drastic shift towards the enhanced expression of survival genes (wild type
survivin, NF 68, NF 200) following SurR9-C84A treatments.
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tion achieved through the carbodiimide chemistry revealed successful
TFN conjugation with almost 75% NPs showing the presence of
TFN and showed an internalization of 90% upon incubation (Fig. 1D).
Preliminarily, D-Gal induced insults were evaluated in vitro, where
untreated D-Gal control showed enhanced, pathologic β-amyloid and
reduced β-tubulin III expression. Contrast results were observed in the
cells pre-treated with SurR9-C84A and positive control melatonin
(Fig. 2A–D). However, only the TFN conjugated SurR9 NPs showed a
signiﬁcant improvement against the D-Gal induced oxidative stress
(Supplementary Figure S2). The current results were also similar to pre-
vious reports where the D-Gal induced oxidative stress and β-amyloid
expression were proportionate to each other (Fig. 4D) [42]. The exact
mechanism of how D-Gal induces behavioural impairment is still
unknown, but there are speculations that the oxidative stress induced
neurodegeneration might be the reason behind it [4].
Interesting theorywas also reportedwhere amaximumbehavioural
impairment was observed at 120 mg/kg dose and self-limitation of this
effect at N200 mg/kg [5]. When implied in this study, a progressivedecline in the motor activity was observed reaching its peak in the 6th
week. However, only the melatonin and SurR9 + TFN NPs treated
groups were observed to be positively inﬂuenced in overcoming the
behavioural compromise. D-Gal insults also reﬂected noticeable changes
in the expression of APP, GSK-3 and Cas-3, APP and GSK-3. All of these
are the pathologic hallmarks of AD associated with the β-amyloid ag-
gregation and tau phosphorylation [43]. Surprisingly, D-Gal also showed
an elevated expression of survivin and mature differential marker that
has been predicted as the neuronal survival responses. With respect to
the treatments, all of themwere very effective in lowering the patholog-
ic markers and in particular SurR9-C84A showed an enhanced expres-
sion of survivin, integrity marker NF 68 and its splice variant Sur3β
indicating extensive protective activity (Fig. 4C). The morphology
analysis depicted a clear picture of neuronal degeneration evident
with pyknotic nuclei, reduced cytoplasmic staining, enlarged vacuoles
and erythrocytes post D-Gal insults (Fig. 4A). Further, histology results
revealed enhanced β-amyloid, cas-3, survivin and reduced NF 68
and NF 200 expression substantiating D-Gal induced neuronal injury.
Interestingly, the EAAT2 expression was also observed to be lowered
Fig. 4. Neuroprotective activity of the nanoformulations. A) D-Gal induced insults showed pyknotic nuclei, lighter cytoplasmic staining (H & E) and increased expression of pathologic β-amyloid and Cas-3 expression. Arrow head showing the
capillaries surrounded by erythrocytes B) Treatments showed reduced expression of excitatory amino acid transporter, glutamate andNMDA receptors in contrast to D-Gal insults. C) Neuronal recovery following the enhanced expression of integrity
markers survivin, neuroﬁlament 68 and 200 post treatments. The representative images from coronal brain sections are presented; n= 3; scale bar = 50 μm. All the images were shown in 40× objective. D) Histogram showing the comparative
expression of pathologic and integrity markers. E) Biodistribution of anti-transferrin antibody conjugated and non-conjugated SurR9-C84A nanoparticles. SurR9-C84A with TFN antibody showed a brain speciﬁc localization and therefore has
shown a maximum therapeutic outcome. *p b 0.05, **p b 0.01, and ***p b 0.001 are considered statistically signiﬁcant.
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Fig. 5. Reduced reactive astrogliosis. A) Immunoﬂuorescence conﬁrmed the astrocytes reactivity following D-Gal insults with enhanced GFAP expression. The treatments however were
effective in reducing the GFAP expression and were evident with the reduced FITC intensity (green channel). The representative images from coronal brain sections are presented;
scale bar = 0–50 μm. All the images were shown in 40× objective. B) Histogram for GFAP expression. See supplementary Figs. S1A & S1B for detailed information.
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severity to the glutamate clearance. EAAT2 is a vital glutamate trans-
porter regulating its clearance, Ca2+ overload and several neurodegen-
erative studies have documented reduced EAAT2 expression [44,45].
Glutamate receptors showed an enhanced expression following
D-Gal insults but the other excitatory receptor, NMDA was not signiﬁ-
cantly affected proving the excess glutamate involvement in this study
(Fig. 4B). However, treatments showed contradicting D-Gal insults and
showed much improved neuronal health (Fig. 4A-D).
The biodistribution studies also conﬁrmed the enhanced brain spe-
ciﬁc permeation of anti-transferrin antibody conjugated SurR9-C84A
and it is believed to be the reason behind improved therapeutic
outcome (Fig. 4E). GFAP, a reactive astrocyte marker has also showed
a differential expressionwith andwithout treatments post D-Gal insults.
Astrocytes represent the primary glial cell population and play a key
role in maintaining the neuronal homeostasis. However, in the in-
stances of neurodegenerative insults they respond viciously initiating
the inﬂammatory reactions, neurotoxic secretions and express elevatedlevels of GFAP marking the astrogliosis phenomenon [46]. Altogether,
the in vitro results were optimistic and hence the protective effects
of the nanoformulations were evaluated in vivo. In the present study,
we used melatonin as a positive control to compare the efﬁcacy of
treatment groups, as it had strong anti-oxidant activity protecting the
neurons [47] (Supplementary Figure S2). To conclude, SurR9-C84A
NPs showed promising activity modifying the oxidative stress and
abrogated the neuronal degeneration providing a basis for future
therapeutic approach (Fig. 6).
5. Conclusion
The current study shows that chronic D-Gal administration induces
oxidative stress and neurodegeneration associated with behavioural
compromise. As a proof of concept, we have shown for the very
ﬁrst time that the surface functionalization of biodegradable, PLGA
nanocarriers decorated with the anti-transferrin receptor antibodies is
a promising approach for enabling the permeation and delivery of
Fig. 6. Schematic representation of neuroprotective effect of nanoformulations. A) Reactive astrocytes with GFAP expression. B) Oxidative stress induced β-amyloid expression.
C) Neuronal damage. D) Small sized SurR9-C84A nanoparticles permeate through the brain capillary endothelium while the anti-transferrin receptor antibody conjugated SurR9-C84A
nanoparticles internalized via the receptor mediated endocytosis. E) Neuroprotective effect. F) Neuronal recovery.
2430 B. Sriramoju et al. / Biochimica et Biophysica Acta 1852 (2015) 2423–2431SurR9-C84A inside the brain through BBB. Moreover, the NPs also
enhanced the bioavailability of SurR9-C84A, thus enabling the differen-
tiation and viability of the neurons. Altogether, the current report on
the neuroprotective activity of SurR9-C84A-NPs is the ﬁrst of its
kind and future studies warrant the study of transferrin targeted
nano-aptamers for further evaluation.Author's contributions
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